Trials / Completed
CompletedNCT01880723
Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis
Modifying Genes in Cystic Fibrosis: The Beta-2 Adrenergic Receptors and Epithelial Na+ Channels
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- University of Arizona · Academic / Other
- Sex
- All
- Age
- 15 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Our aims were to determine if exhaled breath condensate (EBC) could detect differences in ion regulation between cystic fibrosis (CF) and healthy and measure the effect of the albuterol on EBC ions in these populations. We hypothesized EBC chloride and sodium would be lower in CF patients at baseline and that albuterol would decrease EBC sodium and increase EBC chloride.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Albuterol | 2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer |
| DRUG | Placebo saline | nebulized 3mL normal saline) using a Power Neb2 nebulizer |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2012-07-01
- Completion
- 2013-01-01
- First posted
- 2013-06-19
- Last updated
- 2023-11-29
- Results posted
- 2014-06-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01880723. Inclusion in this directory is not an endorsement.